Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Thromboprophylaxis in multiple myeloma: is the evidence there?

× No keyword cloud information.

23 in total

1. Prevention and treatment of venous thromboembolism among patients with cancer: the American Society of Clinical Oncology Guidelines.

Authors: Gary H Lyman; Nicole M Kuderer
Journal: Thromb Res Date: 2010-04 Impact factor: 3.944

2. Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide.

Authors: Alessandra Larocca; Federica Cavallo; Sara Bringhen; Francesco Di Raimondo; Anna Falanga; Andrea Evangelista; Maide Cavalli; Anfisa Stanevsky; Paolo Corradini; Sara Pezzatti; Francesca Patriarca; Michele Cavo; Jacopo Peccatori; Lucio Catalano; Angelo Michele Carella; Anna Maria Cafro; Agostina Siniscalchi; Claudia Crippa; Maria Teresa Petrucci; Dina Ben Yehuda; Eloise Beggiato; Tommaso Caravita Di Toritto; Mario Boccadoro; Arnon Nagler; Antonio Palumbo
Journal: Blood Date: 2011-08-11 Impact factor: 22.113

3. Safety of low-dose low-molecular-weight-heparins in thrombocytopenic stem cell transplantation patients: a case series and review of the literature.

Authors: R B Ibrahim; E Peres; R Dansey; M H Abidi; E M Abella; M M Gumma; N Milan; D W Smith; L K Heilbrun; J Klein
Journal: Bone Marrow Transplant Date: 2005-06 Impact factor: 5.483

4. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group.

Authors: S Vincent Rajkumar; Emily Blood; David Vesole; Rafael Fonseca; Philip R Greipp
Journal: J Clin Oncol Date: 2005-12-19 Impact factor: 44.544

5. Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study.

Authors: Sigurdur Y Kristinsson; Ruth M Pfeiffer; Magnus Björkholm; Lynn R Goldin; Sam Schulman; Cecilie Blimark; Ulf-Henrik Mellqvist; Anders Wahlin; Ingemar Turesson; Ola Landgren
Journal: Blood Date: 2010-03-18 Impact factor: 22.113

6. Efficacy of prophylactic warfarin for prevention of thalidomide-related deep venous thrombosis.

Authors: Nadeem Ikhlaque; Vidya Seshadri; Satheesh Kathula; Michael A Baumann
Journal: Am J Hematol Date: 2006-06 Impact factor: 10.047

7. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial.

Authors:
Journal: Lancet Date: 2000-04-15 Impact factor: 79.321

8. Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines.

Authors: M Mandalà; A Falanga; F Roila
Journal: Ann Oncol Date: 2011-09 Impact factor: 32.976

9. Effective prophylaxis of thromboembolic complications with low molecular weight heparin in relapsed multiple myeloma patients treated with lenalidomide and dexamethasone.

Authors: Ulrike Klein; Florentina Kosely; Jens Hillengass; Michael Hundemer; Stefan Schmitt; Kai Neben; Thomas Moehler; Ute Hegenbart; Anthony D Ho; Hartmut Goldschmidt
Journal: Ann Hematol Date: 2008-07-31 Impact factor: 3.673

10. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.

Authors: Meletios Dimopoulos; Andrew Spencer; Michael Attal; H Miles Prince; Jean-Luc Harousseau; Anna Dmoszynska; Jesus San Miguel; Andrzej Hellmann; Thierry Facon; Robin Foà; Alessandro Corso; Zvenyslava Masliak; Marta Olesnyckyj; Zhinuan Yu; John Patin; Jerome B Zeldis; Robert D Knight
Journal: N Engl J Med Date: 2007-11-22 Impact factor: 91.245